Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial (2022)
- Authors:
- USP affiliated authors: DURIGON, EDISON LUIZ - ICB ; MACHADO, RAFAEL RAHAL GUARAGNA - ICB
- Unidade: ICB
- DOI: 10.1183/13993003.02076-2021
- Subjects: MICROBIOLOGIA; PLASMA; COVID-19; ESTUDOS RANDOMIZADOS; IMUNIZAÇÃO PASSIVA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: European Respiratory Journal
- ISSN: 1399-3003
- Volume/Número/Paginação/Ano: v. 59, n. 2, art. 2101471, p. 1-11, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc
-
ABNT
SEKINE, Leo et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal, v. 59, n. 2, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1183/13993003.02076-2021. Acesso em: 23 maio 2024. -
APA
Sekine, L., Arns, B., Fabro, B. R., Cipolatt, M. M., Machado, R. R. G., & Durigon, E. L. (2022). Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal, 59( 2), 1-11. doi:10.1183/13993003.02076-2021 -
NLM
Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial [Internet]. European Respiratory Journal. 2022 ; 59( 2): 1-11.[citado 2024 maio 23 ] Available from: https://doi.org/10.1183/13993003.02076-2021 -
Vancouver
Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial [Internet]. European Respiratory Journal. 2022 ; 59( 2): 1-11.[citado 2024 maio 23 ] Available from: https://doi.org/10.1183/13993003.02076-2021 - Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice
- A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections
- Anti‐A and SARS‐CoV‐2: an intriguing association
- Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial
- Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?
- Soroprevalência da infecção pelos vírus Zika (ZIKV) e Dengue (DENV) em parturientes e transferência transplacentária de anticorpos anti-ZIKV e anti- DENV em neonatos na cidade de São Paulo, Brasil
- Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing
- Neonatal consequences of maternal exposure to the chikungunya virus
- UV-C (254 nm) lethal doses for SARS-CoV-2
- COVID-19 convalescent plasma cohort study: evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes
Informações sobre o DOI: 10.1183/13993003.02076-2021 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
